Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 61,500 shares, a growth of 55.3% from the March 15th total of 39,600 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 44,900 shares, the short-interest ratio is presently 1.4 days.

Hedge Funds Weigh In On Senti Biosciences

A hedge fund recently bought a new stake in Senti Biosciences stock. Renaissance Technologies LLC purchased a new stake in shares of Senti Biosciences, Inc. (NASDAQ:SNTI - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 51,600 shares of the company's stock, valued at approximately $181,000. Renaissance Technologies LLC owned approximately 1.07% of Senti Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.73% of the company's stock.

Senti Biosciences Stock Down 0.4 %

Shares of SNTI stock traded down $0.02 during mid-day trading on Tuesday, reaching $3.96. The stock had a trading volume of 3,786 shares, compared to its average volume of 43,818. The firm's 50 day simple moving average is $3.51 and its 200 day simple moving average is $3.55. The firm has a market cap of $102.85 million, a PE ratio of -0.25 and a beta of 2.32. Senti Biosciences has a one year low of $1.52 and a one year high of $16.94.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($3.13) by $2.46. The business had revenue of $5.86 million for the quarter, compared to the consensus estimate of $2.80 million. Sell-side analysts forecast that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.